Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

Inclusion Criteria: * Huntington's disease (based on DNA testing polyQ \>36) with a UHDRS maximal chorea score of \>10 * patient with concomitant Huntington's medication (anti-depressants, neuroleptics, benzodiazepines) are allowed but the total daily dose and dosing regimen has to be stable for at least one months prior to randomization * female patients without childbearing potential (post-menopausal or surgically sterilized), all patients must using a double-barrier local contraception Exclusion Criteria: * patients with marked cognitive impairment (MMSE less than 18), with presence of psychosis and/or confusional states * patients with a history or presence of renal impairment and/or liver disease Other protocol-defined inclusion/exclusion criteria may apply